Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

Authors von Websky K, Reichetzeder C, Hocher B

Received 8 August 2013

Accepted for publication 24 September 2013

Published 1 November 2013 Volume 2013:9 Pages 681—694


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Karoline von Websky, Christoph Reichetzeder, Berthold Hocher

Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany

Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenient, once-daily dosing does not need adjustment in patients with hepatic and/or renal impairment. In clinical studies linagliptin shows an important reduction of blood glucose with an overall safety profile similar to that of placebo. So far, the combination of linagliptin and insulin has been tested in three major clinical studies in different populations. It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment. Favorable effects regarding the counteraction of hypoglycemia make linagliptin especially interesting as an add-on therapy to insulin. This review aims to present the existing clinical studies on the efficacy and safety of linagliptin as add-on therapy to insulin in patients with T2DM in the context of current literature. Additionally, the possible advantages of linagliptin as an add-on therapy to insulin in relation to cardiovascular safety, patient-centered therapy and the prevention of hypoglycemia, are discussed.

Keywords: incretin, dipeptidyl peptidase-4, glucagon like peptide-1, glycemic control, renal impairment, hypoglycemia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Readers of this article also read:

Serum uric acid and target organ damage in essential hypertension

Ofori SN, Odia OJ

Vascular Health and Risk Management 2014, 10:253-261

Published Date: 2 May 2014

Dabigatran and myocardial infarction: a foggy scenario

Pontillo D, Patruno N

Vascular Health and Risk Management 2014, 10:45-48

Published Date: 20 January 2014

Release of tissue inhibitor of metalloproteinase-2 from alginate microcapsule encapsulating genetically engineered cells

Kim YS, Jeong YI, Jin SG, Pei J, Wen M, Kim IY, Moon KS, Jung TY, Ryu HH, Jung S

International Journal of Nanomedicine 2013, 8:4351-4359

Published Date: 6 November 2013

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy

Inoue K, Fujimoto T, Higa R, Moriyama R, Kohmoto H, Nagumo H, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:771-775

Published Date: 21 May 2012

Aminopropyltriethoxysilane-mediated surface functionalization of hydroxyapatite nanoparticles: synthesis, characterization, and in vitro toxicity assay

Wang S, Wen S, Shen M, Guo R, Cao X, Wang J, Shi X

International Journal of Nanomedicine 2011, 6:3449-3459

Published Date: 20 December 2011

Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy

Zhang M, Guo R, Wang Y, Cao X, Shen M, Shi X

International Journal of Nanomedicine 2011, 6:2337-2349

Published Date: 14 October 2011

The role of insulin detemir in overweight type 2 diabetes management

Yared N Demssie, Naveed Younis, Handrean Soran

Vascular Health and Risk Management 2009, 5:553-560

Published Date: 29 June 2009

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension

Peter Bramlage

Vascular Health and Risk Management 2009, 5:213-224

Published Date: 11 February 2009


Vascular Health and Risk Management 2006, 2:515-515

Published Date: 15 December 2006